Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 13/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30291997 | 0.81 | CYP4F2 (0.42) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL15666749 | 0.81 | CYP4F2 (0.42) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL22499151 | 0.79 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31179163 | 0.78 | RXRA (0.47) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL22499396 | 0.76 | ALDH1A1 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL22499222 | 0.74 | RXRA (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL476884 | 0.74 | RXRA (0.42) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL19915965 | 0.73 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30811724 | 0.73 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL22499056 | 0.73 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-113905787-A | METTL3 inhibiting compounds | 斯托姆治疗有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | CYP4F2 1288/4885CYP4A11 2029/4885RXRA 3680/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | CYP4F2 1666/4885CYP4A11 2593/4885RXRA 3396/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | CYP4F2 1288/4885CYP4A11 2029/4885RXRA 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.